Alphamab Oncology (9966.HK)
HKSE · HKD · Healthcare · Biotechnology
HK$6.50 (-3.99%) as of
Key statistics
- Market cap
- 6.28B
- Forward P/E
- -20.49
- EPS (TTM)
- -0.200
- Dividend yield
- 0.00%
- 52-week range
- 5.870 – 12.330
- Beta
- 0.55
- Revenue (TTM)
- 518.03M
- Profit margin
- -33.97%
- Analyst target
- HK$9.97
- Volume
- 704.00k
About Alphamab Oncology
Alphamab Oncology, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of biotherapeutics for cancer treatment in the People's Republic of China. It offers KN035, an injectable PD-L1 inhibitor for the treatment of adult patients with unresectable or metastatic microsatellite instability-high/efficient mismatch repair advanced solid tumors under the ENWEIDA brand. Its product pipeline includes KN026, an anti-human epidermal growth factor receptor 2 (HER2) bispecific monoclonal antibody (BsAb) that is in Phase III clinical trials to treat HER2-positive breast cancer and HER2-positive gastric cancer or gastroesophageal junction cancer; KN046, a BsAb immune checkpoint inhibitor in Phase III clinical trial for the treatment of non-small cell lung cancer (NSCLC), squamous NSCLC, triple-negative breast cancer, and recurrent and metastatic esophageal squamous cell carcinoma; JSKN003, a biparatopic HER2-targeting antibody-drug conjugate (ADC) that is in Phase III clinical trial to treat HER2-expressing advanced or metastatic solid tumors, HER2-low expression breast cancer, platinum-resistant recurrent epithelial ovarian cancer, primary peritoneal cancer, and fallopian tube cancer. In addition, the company is developing JSKN016, a bispecific ADC that is in Phase II clinical trial for the treatment of solid tumors, lung cancer, and breast cancer; JSKN022, a bispecific single-domain antibody; JSKN027, a bispecific ADC that is Phase I clinical trial; JSKN021; KN019; and JSKN033, a subcutaneous ADC in Phase I clinical trial to treat HER2-expressing advanced or metastatic solid tumors. The company also develops JSKN029, a pre-clinical stage product for oncology applications. Alphamab Oncology was founded in 2008 and is headquartered in Suzhou, the People's Republic of China.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Suzhou, China
- Employees
- 515
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.